Department of Cancer Research and Molecular Medicine, Faculty of Medicine, Norwegian University of Science and Technology, N-7491 Trondheim, Norway.
J Biol Chem. 2011 May 13;286(19):16669-80. doi: 10.1074/jbc.M111.230052. Epub 2011 Mar 23.
Genomic uracil is a DNA lesion but also an essential key intermediate in adaptive immunity. In B cells, activation-induced cytidine deaminase deaminates cytosine to uracil (U:G mispairs) in Ig genes to initiate antibody maturation. Uracil-DNA glycosylases (UDGs) such as uracil N-glycosylase (UNG), single strand-selective monofunctional uracil-DNA glycosylase 1 (SMUG1), and thymine-DNA glycosylase remove uracil from DNA. Gene-targeted mouse models are extensively used to investigate the role of these enzymes in DNA repair and Ig diversification. However, possible species differences in uracil processing in humans and mice are yet not established. To address this, we analyzed UDG activities and quantities in human and mouse cell lines and in splenic B cells from Ung(+/+) and Ung(-/-) backcrossed mice. Interestingly, human cells displayed ∼15-fold higher total uracil excision capacity due to higher levels of UNG. In contrast, SMUG1 activity was ∼8-fold higher in mouse cells, constituting ∼50% of the total U:G excision activity compared with less than 1% in human cells. In activated B cells, both UNG and SMUG1 activities were at levels comparable with those measured for mouse cell lines. Moreover, SMUG1 activity per cell was not down-regulated after activation. We therefore suggest that SMUG1 may work as a weak backup activity for UNG2 during class switch recombination in Ung(-/-) mice. Our results reveal significant species differences in genomic uracil processing. These findings should be taken into account when mouse models are used in studies of uracil DNA repair and adaptive immunity.
基因组中的尿嘧啶是一种 DNA 损伤物,但也是适应性免疫的关键中间产物。在 B 细胞中,激活诱导的胞嘧啶脱氨酶将胞嘧啶脱氨为尿嘧啶(U:G 错配),从而启动抗体成熟。尿嘧啶-DNA 糖基化酶(UDGs),如尿嘧啶 N-糖基化酶(UNG)、单链选择性单功能尿嘧啶-DNA 糖基化酶 1(SMUG1)和胸腺嘧啶-DNA 糖基化酶,从 DNA 中去除尿嘧啶。基因靶向小鼠模型被广泛用于研究这些酶在 DNA 修复和 Ig 多样化中的作用。然而,人类和小鼠中尿嘧啶处理的种间差异尚未确定。为了解决这个问题,我们分析了人类和小鼠细胞系以及 Ung(+/+)和 Ung(-/-)回交小鼠脾脏 B 细胞中的 UDG 活性和数量。有趣的是,由于 UNG 水平较高,人类细胞的总尿嘧啶切除能力高约 15 倍。相比之下,小鼠细胞中的 SMUG1 活性高约 8 倍,占总 U:G 切除活性的约 50%,而人类细胞中不到 1%。在活化的 B 细胞中,UNG 和 SMUG1 的活性与我们在小鼠细胞系中测量的活性相当。此外,SMUG1 活性在细胞被激活后并未下调。因此,我们认为 SMUG1 可能在 Ung(-/-)小鼠的类别转换重组中作为 UNG2 的弱备用活性。我们的研究结果揭示了基因组中尿嘧啶处理的显著种间差异。在研究尿嘧啶 DNA 修复和适应性免疫时,应考虑这些发现。